FP
NKTR icon

Financial Perspectives’s Nektar Therapeutics NKTR Stock Holding History

Financial Perspectives’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-52
Closed -$14K – 669
2021
Q3 		$14K Hold
52
– – 0.01% 403
2021
Q2 		$13.4K Sell
52
-988
-95% -$273K 0.01% 432
2021
Q1 		$780K Buy
1,040
+988
+1,900% +$308K 0.04% 237
2020
Q4 		$13.3K Hold
52
– – 0.01% 376
2020
Q3 		$12.9K Hold
52
– – 0.01% 342
2020
Q2 		$18.1K Hold
52
– – 0.01% 287
2020
Q1 		$13.9K Hold
52
– – 0.01% 284
2019
Q4 		$16.8K Buy
+52
New +$15.1K 0.01% 281

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Financial Perspectives's NKTR Position: Q4 2021 in Review

Financial Perspectives sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 52 shares — an estimated $14K sold.

Financial Perspectives first reported a position in NKTR in Q4 2019 and held it in 8 quarters. The position peaked at $780K in Q1 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Financial Perspectives reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Financial Perspectives sold 52 Nektar Therapeutics shares in Q4 2021, an estimated $14K.
  • Financial Perspectives first reported a position in Nektar Therapeutics in Q4 2019 and held it in 8 quarters.
  • Financial Perspectives's Nektar Therapeutics position peaked at $780K in Q1 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Financial Perspectives's 13F filing for Q4 2021, filed 10 Jan 2024.